16 results about "MHC class II" patented technology

This disclosure relates to KRAS immunogenic peptides and their uses. According to this disclosure, the KRAS immunogenic peptides selectively bind to MHC class II in a preferential mode to selectively enhance the immunogenicity of specific immune cells capable of killing cancer cells, and thus can be advantageously used as superior cancer vaccines for the prevention and / or treatment of cancer by minimizing immune escape mechanisms of cancer cells.

Disclosed herein are engineered cells and / or hypoimmunogenic cells including engineered cells and / or hypoimmunogenic stem cells, engineered cells and / or hypoimmunogenic cells differentiated therefrom, and / or engineered cells and / or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and / or hypoimmunogenic stem cells) and related methods of their use and generation comprising regulatable reduced expression of one or more MHC class I and / or MHC class II human leukocyte antigen molecules and regulatable overexpression of CD47. Provided herein are cells further exhibiting reduced expression of T-cell receptors.

Provided herein are compositions comprising a liposome comprising RNA molecules and a cationic lipid, wherein the RNA molecules encode at least one MHC Class II epitope of a mutant Histone 3 (H3) protein comprising a K27M mutation and optionally at least one MHC Class I epitope of the mutant H3 protein. In exemplary embodiments, the RNA molecules comprise a sequence of SEQ ID NO: 12 or 14. Methods of increasing central memory T cells, increasing an immune response, or treating a diffuse midline glioma (DMG), in a subject are provided herein. In exemplary embodiments, the methods comprise administering to the subject the compositions provided herein.

The present disclosure provides engineered T cells with reduced expression or knock out of an immunophilin, and which express a chimeric antigen receptor (CAR) and / or comprise one or more modifications that disrupt MHC class I and / or MHC class II alleles and increase expression of a tolerogenic factor. The present disclosure also provides methods of treating a subject having or suspected of having a post-transplant disorder by administering T cells with reduced expression or knock out of an immunophilin. Also disclosed are pharmaceutical compositions comprising T cells with reduced expression of an immunophilin, for use in treating a subject having or suspected of having a post-transplant disorder.

Recent evidence accumulating over the last decade demonstrates that generation of CD4+ T cells is critical for sustained immunity against Bordetella pertussis. B. pertussis contains hundreds of antigens that are processed and presented on MHC Class II and recognized by CD4′T cells. The present disclosure relates to a vaccine comprising Bordetella pertussis antigen peptides to prevent infection of the Bordetella pertussis bacterium.

Provided herein are methods of administering engineered islet cells, including functionally modified beta cells containing one or more modifications (such as genetic modifications). In some embodiments, the engineered pancreatic islets are low immunogen cells. In some embodiments, the one or more modifications reduce or eliminate the expression of one or more MHC class I and / or MHC class II human leukocyte antigens, while increasing the expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related condition, such as diabetes (e.g., type I diabetes).

Disclosed herein are methods for predicting tumor-specific neoantigen MHC class I or MHC class II immunogenicity by jointly predicting MHC class I or MHC class II binding affinity and predicting the likelihood a tumor-specific neoantigen will be presented by a MHC class I or class II protein on a cell-surface.

The present invention relates to a method for assessing disease severity or a clinical stage of, or predicting prognosis for chemotherapy in, dogs suffering from lymphoma. According to the present invention, in dogs suffering from lymphoma, it has been confirmed that CD34-positive expression is associated with a higher risk of cranial mediastinal lymph node metastasis and fever compared to CD34-negative expression; and since the CD34-positive expression is classifiable as a clinical disease within the WHO clinical substages, CD34 positivity can serve as an indicator of poor prognosis. In addition, it has been confirmed that MHC class II (MHCII)-positive expression is associated with a higher risk of fever and adverse effects from chemotherapy compared to MHCII-negative expression, and thus can serve as an indicator of favorable prognosis. Accordingly, the present invention may contribute not only to preserving companion dog health and reducing medical expenses for pet owners, but also to improving the quality of veterinary consultations.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

Provided herein are methods of producing engineered target organs (e.g., a pancreas) and / or cells therefrom (e.g., islets) using a non-human mammal host. In some embodiments, the methods relate to injecting hypoimmunogenic human pluripotent stem cells (HIP-hPSC) into a blastocyst of a surrogate non-human mammal to produce a chimeric blastocyst and implanting the chimeric blastocyst into the uterus of the surrogate non-human mammal, wherein after implantation the chimeric blastocyst develops into a non-human mammal host comprising a target organ with chimeric contribution from the HIP-hPSCs. In further embodiments, the target organ and / or cells therefrom are transplanted into a human subject having a disease or condition. In some embodiments, the HIP-hPSCs comprise one or more modifications that reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors.

Disclosed herein are engineered cells and / or hypoimmunogenic cells including engineered and / or hypoimmunogenic stem cells, engineered and / or hypoimmunogenic cells differentiated therefrom, engineered and / or hypoimmunogenic CAR-T cells (primary or differentiated from engineered and / or hypoimmunogenic stem cells) and related methods of their use and generation. Provided herein are engineered and / or hypoimmunogenic cells exhibiting reduced expression of MHC class I and / or MHC class II human leukocyte antigens and T-cell receptors. In some embodiments, such cells also exogenously express one or more tolerogenic factors such as CD47 and one or more chimeric antigen receptors (CAR)s.

The application provides an antigen detection system and method thereof, comprising: a variation detection module, configured to receive tumor genome sequencing data and normal genome sequencing data, process the tumor genome sequencing data and the normal genome sequencing data using a GATK tool to detect somatic mutations of SNV / INDEL types of the tumor, detect variations of a gene fusion type by using STARfusion software, detect variations of a variable splicing type by using NeoSplice software, and be capable of connecting external existing gene variation detection data; and an HLA typing module, configured to receive the tumor genome sequencing data and the normal genome sequencing data. The antigen detection system and method thereof provided by the application can comprehensively analyze and obtain a candidate neoantigen list from the tumor genome sequencing data, cover multiple gene variation types (SNV / INDEL, gene fusion, variable splicing), and have detection capabilities of MHC class I and MHC class II and HLA typing capabilities, so that more comprehensive antigen information is provided for tumor immunotherapy.

The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of mammary / breast carcinomas, in particular locally recurring or metastasizing mammary carcinomas in a patient or group of patients, who has or is suspected of having a breast carcinoma, comprising at least 4 to 8 HLA-A tumor antigen peptides corresponding to MHC class I complexes and at least 2 tumor antigen peptides corresponding to MHC class II complexes, wherein the HLA tumor antigen peptides are tumor-exclusive or tumor-associated HLA antigen peptides and are directed against at least one MHC complex including combinations thereof; a pharmaceutical composition, a kit (or parts thereof); a method for determining an HLA peptide of class I and / or II; a method for preparing a pharmaceutical composition according to the invention; and the use of a pharmaceutical composition according to the invention for the preparation of a pharmaceutical composition for the treatment of malignancies, leukemias and neoplasms.

Provided herein are methods of dosing engineered islet cells that include functional modified beta cell containing one or more modifications, such as genetic modifications. In some embodiments, the engineered islets are hypoimmunogenic cells. In some embodiments, the one or more modifications reduce or eliminate expression of one or more MHC class I and / or MHC class II human leukocyte antigens and also increase expression of one or more tolerogenic factors, such as CD47. In some embodiments, the subject has a beta cell related disorder, such as diabetes (e.g. Type I diabetes).

Disclosed herein are methods for predicting tumor-specific neoantigen MHC class I or MHC class II immunogenicity by jointly predicting MHC class I or MHC class II binding affinity and predicting the likelihood a tumor-specific neoantigen will be presented by a MHC class I or class II protein on a cell-surface.

The present disclosure provides engineered T cells with reduced expression or knock out of an immunophilin, and which express a chimeric antigen receptor (CAR) and / or comprise one or more modifications that disrupt MHC class I and / or MHC class II alleles and increase expression of a tolerogenic factor. The present disclosure also provides methods of treating a subject having or suspected of having a post-transplant disorder by administering T cells with reduced expression or knock out of an immunophilin. Also disclosed are pharmaceutical compositions comprising T cells with reduced expression of an immunophilin, for use in treating a subject having or suspected of having a post-transplant disorder.